The firm said it needs more time to ensure that the DetermaVu assay is providing the most consistent and sensitive results for patients.
Presentations at this month's ASCO meeting demonstrated how efforts are advancing to determine when and how longitudinal ctDNA testing will be useful for oncologists.
MSK-ACCESS sequences 129 cancer-associated genes selected from the MSK-IMPACT assay and is designed to detect gene alterations in cfDNA specimen.
The University of Arkansas researchers aim to commercialize the Cytophone platform, in development since 2003, by launching a startup in the next year.
Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.
The Patent Trial and Appeal Board has denied Foundation Medicine's request for Inter Partes review.
The Swedish company is developing sequencing- and PCR-based tests and services that quantify aberrations in DNA, RNA, and circulating tumor DNA.
Exact Sciences and the Mayo Clinic are working to develop a blood test for pancreatic cancer that might be able to diagnose patients with early-stage disease.
The company reported that its genome-wide methylation approach could detect 77 percent of stage II cancers in its ongoing case-control CCGA study.
Thrive Earlier Detection is banking on targeted detection of frequent cancer mutations, coupled with protein markers, while competitors turn to genome-wide approaches.
The company is commercializing a method developed by researchers at Johns Hopkins that detects cancer with high specificity from a blood sample.
The test will be used to identify which advanced or metastatic breast cancer patients with PIK3CA mutations are likely to respond to Novartis' alpelisib.
Investigators concluded that the spiked samples from SeraCare were a robust tool for inter-lab comparisons and discussed some areas of discordance seen in the study.
The firm plans to use the funds raised to support business activities, as it moves forward in the development of cancer early detection tests.
The company said adopters are ordering tests in areas of great interest, like CTC and blood biomarker monitoring, despite a lack of reimbursement.
The company estimated that the offering could raise between $327.2 and $376.3 million, which it would use for various corporate purposes.
Shares jumped nearly 90 percent today after the firm said this morning that it has commercially launched its Target Selector NGS Lung Panel assay.
The test will guide clinical decision making related to Inovio's DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus.
PGDx, the defendant in the liquid biopsy IP case, has alleged that Guardant's CEO should have been named as an inventor on patents but was purposefully left off.
The firm is conducting validation studies on its lung cancer test and continues to anticipate commercializing it in the second half of this year.